Ispronicline (Targacept).
Targacept (formerly a subsidiary of RJ Reynolds) is developing ispronicline, the lead in a series of nicotinic acetylcholine (nACh) ligands, as a potential oral treatment for cognitive impairment, including a variety of non-Alzheimer's dementias. In July 2005, Targacept was preparing for a phase II study in patients with mild-to-moderate Alzheimer's disease.
Geerts
Hugo
H
In Silico Biosciences Inc, 3741 Walnut Street #609, Philadelphia, PA 19104, USA. Hugo-Geerts@In-Silico-Biosciences.com
D000818:Animals; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D015394:Molecular Structure; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000378:metabolism*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D011725:Pyridines; D011978:Receptors, Nicotinic; C490152:ispronicline